Drug Profile
Liafensine - Denovo Biopharma
Alternative Names: BMS-820836; DB 104Latest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator AMRI
- Developer Bristol-Myers Squibb; Denovo Biopharma
- Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders
- Preclinical Major depressive disorder
Most Recent Events
- 03 Apr 2024 Efficacy and adverse event data from the phase IIb ENLIGHTEN trial in Major depressive disorder released by Denovo Biopharma
- 04 Mar 2024 Denovo Biopharma completes a phase II ENLIGHTEN trial in Depressive disorders (Treatment-resistant) in USA & Canada (PO) (NCT05113771)
- 06 Mar 2023 Denovo Biopharm receives approval for phase IIb ENLIGHTEN trial of liafensine for Depressive disorders (Treatment-resistant) from the regulatory agencies in the US, Canada and China